ClinicalTrials.gg
RecruitingNCT07845604PDATUpdated Nov 12, 2026

Precision Depression Adalimumab Trial

A Phase 2 interventional study of Adalimumab Biosimilars Injection and Placebo in Major Depressive Disorder (MDD), sponsored by Daniel Moriarity. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Daniel Moriarity · Phase 2, Interventional, and Treatment

Updated Nov 12, 2026Start date movedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.

Planned enrollment
703rd of 1,323
60 · median 70
Started
2026
with 81 others
Phase 2
271 of 1,500
45 open now
Primary completion
2031-07
later than 251 of 258 live
Registered
1,488th of 1,500
by date

Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 703rd largest by planned enrollment of the 1,323 interventional ones that give a count, is one of 82 that started in 2026, is one of 271 in phase 2, reaches primary completion later than 251 of the 258 other live ones, and was the 1,488th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:

209 more — sign in →

All 215 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,500 studies in Depressive Disorder, Major with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if the anti-inflammatory medication adalimumab improves depressive symptoms in adults with Major Depressive Disorder (MDD) who are already taking the anti-depressant medication Lexapro (escitalopram).

The main questions it aims to answer are:

  1. Does adalimumab improve the symptoms of some patients with MDD who are already taking an anti-depressant?
  2. What characteristics predict for whom adalimumab has anti-depressant properties.

Researchers will compare adalimumab to a placebo (a look-alike substance that contains no drug) to see if adalimumab works to improve depressive symptoms as an add-on drug to the anti-depressant Lexapro (escitalopram).

For these primary aims the participants will:

  1. Visit the clinic once every 2 weeks for a checkups and injection of adalimumab or placebo from the study psychiatrist (Day 1, 15, 29, and 43 for injections)
  2. Complete short (\<5 min) daily surveys for the 57 day duration of the study.
Read the detailed description

This is a 57-day intensive longitudinal study of 60 adult subjects with Major Depressive Disorder and elevated baseline tumor necrosis factor (TNF) levels. A triple-blind, placebo-controlled pharmacological investigation of adalimumab as an adjunctive medication to escitalopram will be conducted to determine anti-depressant efficacy of adalimumab. Patients will be screened for depression, health concerns, and a minimum of 1.5 pg/mL TNFa. It is hypothesized that adalimumab will lead to improved treatment outcomes (specifically somatic/neurovegetative symptoms). It is hypothesized that, if more symptoms than somatic/neurovegetative respond, they will do so less quickly than somatic/neurovegetative symptoms.

Enrolled participants will be randomized in a 2:1 ratio to adjunctive adalimumab or placebo in addition to the participant's regular dose of escitalopram each day (both conditions). Patients will be matched for sex. Enrolled patients will attend 4 clinic visits, at which point they will receive injections of adalimumab or placebo from the study psychiatrist (Day 1, 15, 29, and 43 for injections), in addition to clinician-assessed measures. Daily self-report assessments of depression symptoms will be collected for 57 days.

03

Conditions studied

  • Major Depressive Disorder (MDD)

Keywords

  • inflammation
  • depression
  • psychoneuroimmunology
  • intensive longitudinal study
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged 18+ years
  • Meet criteria for Major Depressive Disorder
  • baseline serum TNF-alpha (average of two samples in the same week) greater than 1.5 pg/mL
  • Taking a steady dose of Lexapro (escitalopram) for at least 4 weeks
  • Ability to take oral medication and physician-administered subcutaneous injection and be willing to adhere to the study protocol
  • For females of : use of highly effective for at least 1 month
  • Access to a phone or computer with a camera

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breastfeeding
  2. Active, chronic or recurrent infection
  3. Known
  4. Current use of immune modulating medications
  5. , current condition or history of severe immune condition (e.g., history of cancer, /AIDS)
  6. History of, or positive test for, surface antigen or core antibody positivity or tuberculosis (TB)
  7. Congestive heart failure
  8. History of demyelinating disease (multiple sclerosis (MS), optic neuritis, Guillain-Barre syndrome)
  9. History of seizure disorder
  10. Symptomatic hyponatremia
  11. Monoamine oxidase inhibitors (MAOI) use within 14 days
  12. Recent use of Rituxan (rituximab)
  13. Concomitant use of:

    1. Immunosuppressants
    2. Kineret (anakinra)
    3. Orencia (abatacept)
    4. Remicade (infliximab)
    5. Enbrel (etanercept)
    6. Cimzia (certolizumab pegol)
    7. Simponi (golimumab)
    8. Imuran (azathioprine)
    9. Purinethol (6-mercaptopurine)
    10. Linezolid
    11. IV methylene blue
    12. Pimozide
    13. Antiplatelet agents
    14. Strong anticoagulants (e.g. warfarin, large doses of NSAIDs)
    15. Other SSRIs, SNRIs, tryptophan
  14. substance use disorder
  15. Known allergic reactions to components of adalimumab and/or escitalopram
  16. Treatment with another drug or other intervention while participating in the study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Active Treatment Arm

    80 mg adalimumab administered on Day 1 subcutaneously, then 40 mg adalimumab administered on Days 15, 29, and 43 subcutaneously by study psychiatrist.

    Drug: Adalimumab Biosimilars Injection

  • Placebo comparator
    Placebo Comparison Arm

    0.8 mL saline placebo administered on Day 1 subcutaneously, then 0.4 mL saline placebo administered on Days 15, 29, and 43 subcutaneously by study psychiatrist.

    Other: Placebo

Interventions

  • DrugAdalimumab Biosimilars Injection

    adalimumab biosimilar 100mg/mL

  • OtherPlacebo

    placebo injection of same volume as active medication for that visit

    Also known as: saline placebo

06

What researchers measure

Primary outcomes

  1. Change from baseline in individual somatic, affective, and motivational depressive symptoms, as measured by the Quick Inventory of Depressive Symptomatology (QIDS)

    The QIDS (Trivedi et al., 2004; Rush et al., 2003) is a rating scale that assesses the nine criterion symptom domains designated by the American Psychiatric Association's (2000) DSM-IV to diagnose a major depressive episode. There are 16 items in the adult versions of the QIDS16 measuring the nine criterion symptom domains (sleep, sad mood, appetite/weight, concentration/decision making, self-view, thoughts of death or suicide, general interest, energy level, and restlessness/agitation) that define a major depressive episode according to the DSM-IV. The scores for three domains (sleep, appetite/weight, and restlessness/agitation) are based upon the maximum score (most pathological) of two or more questions for the total score analysis. Each of the remaining domains is rated by a single item. All domains are scored from 0 to 3, with higher scores reflecting greater psychopathology. Source: Yeung, A. et al. (2012). The QIDS. The Journal of nervous and mental disease, 200(8), 712-715.

    Time frame: From start of trial to the end of study (Day 57)

Secondary outcomes

  1. Change from baseline in the total depression score, as measured by the Quick Inventory of Depressive Symptomatology

    as for primary

    Time frame: From start of trial to the end of study (Day 57)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani P. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol. 2010 May;62(5):812-8. doi: 10.1016/j.jaad.2009.07.022. Epub 2010 Mar 9. PubMed 20219265 ↗
  • Abbasian F, Bagheri S, Moradi K, Keykhaei M, Etemadi A, Shalbafan M, Shariati B, Vaseghi S, Samsami FS, Akhondzadeh S. Evidence for Anti-inflammatory Effects of Adalimumab in Treatment of Patients With Major Depressive Disorder: A Pilot, Randomized, Controlled Trial. Clin Neuropharmacol. 2022 Sep-Oct 01;45(5):128-134. doi: 10.1097/WNF.0000000000000518. Epub 2022 Sep 7. PubMed 36093920 ↗

Individual participant data

Plan to share: Yes — Publication-specific

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: data necessary to reproduce analyses will be shared with reviewers before publication and available after in perpetuity

Access criteria: open access after publication

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jul 2031, 56 months later.

Of 99 non-industry phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 57. This study's planned 56 months is above that.

Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Sep 29, 2026
StartEst.
Nov 2026was Sep 2026
Primary completionEst.
Jul 2031
CompletionEst.
Sep 2031
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2026→Nov 2026
Nov 12, 2026
Registered
First appeared on the registry
Sep 29, 2026
Show all 2 updates
  1. Nov 12, 2026
    Start date Sep 2026→Nov 2026
    + 1 other change: verification date
  2. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07845604
Lead sponsor
Daniel Moriarity
Collaborators
Brain & Behavior Research Foundation
Responsible party
Daniel Moriarity (Assistant Professor of Clinical Psychology, University of Pennsylvania) — Sponsor-investigator
First posted
Sep 29, 2026
Start date
Nov 2026 (estimated)
Primary completion
Jul 2031 (estimated)
Completion
Sep 2031 (estimated)
Last update
Nov 12, 2026

Study contacts

Daniel P Moriarity, PhD
Contact
dmori@upenn.edu
(484) 808-5930
Daniel P. Moriarity, PhD
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion